Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?

Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Eur Heart J. 2019 03 21; 40(12):1009-1012.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.